Related Experiment Video

Updated: Oct 29, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis

Anastasios Kollias1, Konstantinos G Kyriakoulis1, Ioannis G Kyriakoulis1

  • 1Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Greece.

Atherosclerosis
|July 10, 2021
PubMed

Insights

Statin therapy significantly reduces mortality risk in hospitalized COVID-19 patients. This systematic review found statin use associated with a 35% lower risk of death, highlighting their protective effects.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • High cardiovascular risk patients are susceptible to severe COVID-19.
  • Statins possess cardioprotective, immunomodulatory, and anti-inflammatory properties.
  • Understanding statins' impact on COVID-19 mortality is crucial.

Purpose of the Study:

  • To systematically review evidence on statin treatment and COVID-19 mortality.
  • To meta-analyze the association between statin use and mortality in COVID-19 patients.

Main Methods:

  • Systematic PubMed/Embase search (Feb 2020 - Mar 2021).
  • Inclusion of 22 studies reporting adjusted hazard or odds ratios for death.
  • Meta-analysis of hazard and odds ratios from included studies.

Main Results:

  • Meta-analysis of 10 studies (41,807 patients) showed a pooled hazard ratio of 0.65 (95% CI 0.53, 0.81) for mortality in statin users.
  • Meta-analysis of 6 studies on statin continuation during hospitalization revealed a pooled hazard ratio of 0.54 (95% CI 0.47, 0.62).
  • Meta-analysis of 12 studies (72,881 patients) showed a pooled odds ratio of 0.65 (95% CI 0.55, 0.78) for mortality.

Conclusions:

  • Statin therapy is associated with a ~35% reduction in adjusted mortality risk in hospitalized COVID-19 patients.
  • Findings support the continued use of statins in patients with cardiovascular risk during the COVID-19 pandemic.
Abstract

Keywords:
COVID-19DeathMeta-analysisMortalitySARS-CoV-2Statins

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.8K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
69
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
55
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
84
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
81
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
191